Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Otilimab - GlaxoSmithKline

Next Previous
X
Search
Drug Profile

Otilimab - GlaxoSmithKline

Alternative Names: GSK-3196165; GSK165; MOR-103

Latest Information Update: 01 Aug 2024

Price :

$50 *

Note:
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator MorphoSys
  • Developer GlaxoSmithKline
  • Class Anti-inflammatories; Antirheumatics; Monoclonal antibodies
  • Mechanism of Action Granulocyte macrophage colony stimulating factor antagonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes
  • Available For Licensing Yes

Highest Development Phases

  • Discontinued Multiple sclerosis; Osteoarthritis; Rheumatoid arthritis; SARS-CoV-2 acute respiratory disease

Most Recent Events

  • 10 Oct 2023 GlaxoSmithKline terminates the phase III contRAst X trial in Rheumatoid arthritis in United Kingdom, Ukraine, Thailand, Spain, South Africa, Serbia, Russia, Poland, Mexico, Mexico, Czech Republic, Malaysia, Lithuania, Latvia, South Korea, India, Japan, Hungary, Germany, Estonia, Colombia, China, Canada, Bulgaria, Belgium, Australia, Argentina, USA (SC), due to limited efficacy (NCT04333147) (EudraCT2019-000878-30)
  • 24 Feb 2023 GlaxoSmithKline completes a Phase-III contRAst X clinical trial in Rheumatoid arthritis in United Kingdom, Ukraine, Thailand, Spain, South Africa, Serbia, Russia, Poland, Mexico, Mexico, Czech Republic, Malaysia, Lithuania, Latvia, South Korea, India, Japan, Hungary, Germany, Estonia, Colombia, China, Canada, Bulgaria, Belgium, Australia, Argentina, USA (SC) (NCT04333147) (EudraCT2019-000878-30)
  • 26 Jan 2023 GlaxoSmithKline withdraws a phase I trial prior to enrolment for Rheumatoid arthritis (In volunteers) due to the reason of the limited efficacy demonstrated in the ContRAst phase III trial as a potential treatment for rheumatoid arthritis (NCT05304130)

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top